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Kallmann syndrome (KS) is a developmental disease that associates hypogonadism and a
deficiency of the sense of smell. The reproductive phenotype of KS results from the pri-
mary interruption of the olfactory, vomeronasal, and terminal nerve fibers in the frontonasal
region, which in turn disrupts the embryonic migration of neuroendocrine gonadotropin-
releasing hormone (GnRH) synthesizing cells from the nose to the brain. This is a highly
heterogeneous genetic disease, and mutations in any of the nine genes identified so far
have been found in approximately 30% of the KS patients. PROKR2 and PROK2, which
encode the G protein-coupled prokineticin receptor-2 and its ligand prokineticin-2, respec-
tively, are two of these genes. Homozygous knockout mice for the orthologous genes
exhibit a phenotype reminiscent of the KS features, but biallelic mutations in PROKR2 or
PROK2 (autosomal recessive mode of disease transmission) have been found only in a
minority of the patients, whereas most patients carrying mutations in these genes are
heterozygotes. The mutations, mainly missense mutations, have deleterious effects on
PROKR2 signaling in transfected cells, ranging from defective cell surface-targeting of the
receptor to defective coupling to G proteins or impaired receptor-ligand interaction, but
the same mutations have also been found in apparently unaffected individuals, which sug-
gests a digenic/oligogenic mode of inheritance of the disease in heterozygous patients.
This non-Mendelian mode of inheritance has so far been confirmed only in a few patients.
However, it may account for the unusually high proportion of KS sporadic cases compared
to familial cases.
Keywords: PROK2, PROKR2, Kallmann syndrome, hypogonadotropic hypogonadism, anosmia, digenic/oligogenic
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INTRODUCTION
Kallmann syndrome (KS) is a developmental disease that asso-
ciates hypogonadotropic hypogonadism, due to gonadotropin-
releasing hormone (GnRH) deficiency, and anosmia, related to
the absence or hypoplasia of the olfactory bulbs (Kallmann, 1944;
deMorsier, 1954; Naftolin et al., 1971). The degree of the hypog-
onadism and that of the smell deficiency can vary significantly,
not only between unrelated KS patients, but also between patients
from the same family. The prevalence of KS has been estimated at
one out of 8000 in boys. In girls, the prevalence is thought to be
five times lower, but it is probably underestimated because some
affected females only have mild hypogonadism, and also because
primary amenorrhea in females often remains unexplored (Jones
and Kemmann, 1976).
Pathohistological studies of fetuses with olfactory bulb agenesis
have shown that the reproductive phenotype of KS results from a
pathological sequence in embryonic life, whereby premature inter-
ruption of the olfactory, vomeronasal, and terminal nerve fibers in
the frontonasal region disrupts the migration of neuroendocrine
GnRH cells, which normally migrate from the nose to the brain
along these nerve fibers (Schwanzel-Fukuda and Pfaff, 1989; Teix-
eira et al., 2010). What causes the primary failure of these fibers
to establish proper contact with the forebrain is, however, still
unknown.
Kallmann syndrome is genetically heterogeneous and involves
various modes of transmission, specifically, X-chromosome
linked, autosomal recessive, autosomal dominant with incom-
plete penetrance, and also digenic/oligogenic inheritance (Dodé
and Hardelin, 2009; Sykiotis et al., 2010). Because the com-
mon infertility in affected individuals and, most importantly,
the incomplete penetrance of the disease impede genetic linkage
analysis, researchers have used various strategies to identify genes
involved in KS, including mutation screening in genes that are dis-
rupted by deletion or translocation breakpoints in chromosomal
rearrangements associated with the disease phenotype, and can-
didate gene approaches. Nine causal genes have been reported to
date, namely, by chronological order of discovery, KAL1 (Franco
et al., 1991; Legouis et al., 1991; Hardelin et al., 1992), FGFR1
(Dodé et al., 2003), PROKR2 and PROK2 (Dodé et al., 2006),
FGF8 (Falardeau et al., 2008), CHD7 (Kim et al., 2008; Jongmans
et al., 2009), WDR11 (Kim et al., 2010), HS6ST1 (Tornberg et al.,
2011), and SEMA3A (Hanchate et al., 2012; Young et al., 2012)
(Table 1). Various loss-of-function mutations in KAL1, encoding
the extracellular matrix glycoprotein anosmin-1, and in FGFR1 or
FGF8, encoding fibroblast growth factor receptor-1 and fibrob-
last growth factor-8, underlie the X-chromosome linked form
and an autosomal dominant form of KS, respectively. Mutations
in KAL1 and FGFR1/FGF8 account for roughly 8 and 10% of
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Table 1 | KS genes.
Genes KAL1 FGFR1 and FGF8 PROKR2 and PROK2 CHD7 WDR11 HS6ST1 SEMA3A
Mode(s) of
transmission
X-linked recessive Autosomal dominant
(incomplete
penetrance) or
digenic/oligogenic
Autosomal recessive
or digenic/oligogenic
? ? digenic/
oligogenic?
digenic/
oligogenic?
Strategy for gene
identification
Cytogenetics Cytogenetics and
mouse model
Mouse models Candidate gene Cytogenetics C. elegans
model
Mouse
model
Prevalence of
mutations in KS
patients
8% of male
patients
10 and <1% 7 and 3% 1–5% <1% <1% 6%
Reference Legouis et al.
(1991), Franco
et al. (1991),
Hardelin et al.
(1992)
Dodé et al. (2003),
Falardeau et al.
(2008)
Dodé et al. (2006) Kim et al. (2008),
Jongmans et al.
(2009)
Kim et al.
(2010)
Tornberg et al.
(2011)
Hanchate
et al. (2012),
Young et al.
(2012)
?, not known.
all KS cases, respectively. The KAL1 gene product, anosmin-1,
binds to heparan-sulfate glycosaminoglycans, and may act as a co-
receptor for FGF signaling through FGFR1, which also requires
interaction with heparan-sulfate glycosaminoglycans for recep-
tor activation. Mutations in the genes encoding heparan-sulfate
6-O-sulfotransferase 1, an enzyme involved in glycosaminogly-
can modifications, WDR11, an intracellular protein that interacts
with the transcription factor EMX1,and semaphorin 3A,a secreted
protein involved in axonal pathfinding, have also been found in
some KS patients. Mutations in the chromodomain helicase DNA-
binding protein 7 gene (CHD7 ) are present in approximately 70%
of the patients affected by the CHARGE syndrome, which in most
patients includes KS (Pinto et al., 2005), and mutations in this gene
have been found in some patients who initially presented with KS.
Finally, mutations in PROKR2 and PROK2, encoding prokineticin
receptor-2 and prokineticin-2, respectively, have been identified in
approximately 9% of the KS patients, both in heterozygous and in
homozygous or compound heterozygous states.
PROKINETICINS AND THEIR RECEPTORS
Prokineticins are secreted cysteine-rich proteins that possess
diverse biological activities. The first identified member of this
family was isolated from the venom of the black mamba snake
(Joubert and Strydom, 1980), and was named mamba intestinal
toxin 1 (MIT1) owing to its ability to induce intestinal con-
traction (Schweitz et al., 1999). Then, a small protein of similar
size (77 amino acid residues, 8 kDa), with 58% sequence identity
with MIT1, was isolated from skin secretions in the amphib-
ian Bombina variegata, and called Bv8 (Mollay et al., 1999).
Soon after, two mammalian proteins of this family were iden-
tified and named prokineticin-1 and -2 (PROK1 and PROK2)
(Li et al., 2001; Kaser et al., 2003). PROK1 has 80% sequence
identity with MIT1 and 58% identity with PROK2 (Li et al.,
2001). The amino-terminal domain of prokineticins contains a
sequence of six amino acid residues (AVITGA), which is conserved
in all mammalian and non-mammalian orthologs. Substitutions,
deletions, or insertions to this hexapeptide result in the loss of ago-
nist activity on prokineticin receptors (Kaser et al., 2003; Bullock
et al., 2004). The carboxy-terminal region of prokineticins con-
tains 10 cysteine residues forming five disulfide bonds. Apart from
its potent effect on gastrointestinal smooth muscle contraction,
PROK1 was also characterized as an angiogenic factor with spe-
cific effects on steroidogenic glands, thus earning its initial name
EG-VEGF (endocrine gland vascular endothelial growth factor)
(LeCouter et al., 2003). Mouse and human orthologs of Bv8, also
known as PROK2, have been involved in a variety of biological
activities, including effects on neuronal survival, gastrointestinal
smooth muscle contraction (Li et al., 2001), circadian locomotor
rhythm (Cheng et al., 2002), survival and migration of adrenal cor-
tical capillary endothelial cells (LeCouter et al., 2003). PROK2 also
has a role in appetite regulation and its anorectic effect is mediated
partly by the melanocortin system (Gardiner et al., 2006).
Prokineticins can bind to two different G protein-coupled
receptors, prokineticin receptor-1 and -2 (PROKR1 and
PROKR2), which have about 85% sequence identity. These recep-
tors were characterized simultaneously by three different groups
(Lin et al., 2002; Masuda et al., 2002; Soga et al., 2002). Both are
able to bind to PROK1 and PROK2 with similar nanomolar range
affinities. They have a central core formed by seven transmem-
brane α-helical segments (TM1–TM7) connected by intracellular
(i1–i3) and extracellular (e1–e3) loops, an extracellular amino-
terminal end, and an intracellular carboxy-terminal end. These
plasma membrane receptors operate as molecular switches to
relay extracellular ligand-activation to intracellular heterotrimeric
G proteins. PROKR1 is mainly expressed in peripheral tissues,
including endocrine glands and organs of the reproductive system,
the gastrointestinal tract, lungs, and the circulatory system (Soga
et al., 2002; Battersby et al., 2004), whereas PROKR2 shows rela-
tively localized distribution in the central nervous system (Cheng
et al., 2002; Lin et al., 2002).
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The olfactory bulb is one of the few areas in the mammalian
brain that produce neurons throughout life. New interneurons
originating from progenitors in the subventricular zone (SVZ)
are continually added to the olfactory bulbs. The mRNAs of both
receptors (PROKR1 and PROKR2) are expressed in the SVZ and
the olfactory bulbs. The expression of PROKR1 have been detected
in these areas although less abundantly than PROKR2. Whereas
PROK1 mRNAs were not detected in any of these brain region
(Ng et al., 2005). It was first shown that PROK2 functions as a
chemoattractant for these neuronal progenitors, which follow a
rostral migratory stream. Accordingly, PROK2 deficiency in mice
leads to a loss of normal olfactory bulb architecture, and accumu-
lation of neuronal progenitors in the rostral migratory stream (Ng
et al., 2005). Soon after, it was found that Prokr2−/− knockout mice
exhibit early hypoplasia of the olfactory bulbs and severe atrophy
of the reproductive organs in both sexes, a phenotype reminiscent
of the KS features. In addition, immunohistochemical analysis
of these mice revealed that the neuroendocrine GnRH cells were
absent from the hypothalamus (Matsumoto et al., 2006).
PROK2 is a clock-controlled gene: the level of its messenger
RNA shows a circadian oscillation profile in the suprachiasmatic
nuclei (Cheng et al., 2002; Li et al., 2006). It has been postu-
lated that PROK2 signaling through PROKR2 is a suprachias-
matic nuclei clock output signal that regulates circadian rhythms
(Prosser et al., 2007; Li et al., 2012). PROK2-null mice show accel-
erated acquisition of food anticipatory activity during a daytime
food restriction (Li et al., 2006), exhibit reduced total sleep time
predominantly during the light period, and also have an impaired
response to sleep disturbance (Hu et al., 2007).
PROK2 is a functional target gene of proneural basic helix-
loop-helix (bHLH) factors. Neurogenin-1 (NGN1) and MASH1
activate PROK2 transcription by binding to E-box motifs on the
PROK2 promoter with the same set of E-boxes critical for another
pair of bHLH factors, CLOCK and BMAL1, in the regulation of
circadian clock (Cheng et al., 2002; Zhang et al., 2007).
COMPLEX GENETICS OF KALLMANN SYNDROME CAUSED
BY MUTATIONS IN PROKR2 OR PROK2
We first considered that PROKR2 was a relevant KS candidate
because of the KS-like phenotype of PROKR2-null mice (see
above). We thus sequenced the two coding exons of PROKR2 in
a cohort of patients affected by KS, and identified 10 different
mutations (one frame-shifting and nine missense mutations) in
14 patients, either in heterozygous state (10 cases) or in homozy-
gous or compound heterozygous state (4 cases) (Dodé et al.,
2006) (Table 2). Notably, most of these mutations were missense
mutations, and many were also found in apparently unaffected
individuals, thus initially raising some questions regarding their
pathogenic role. A deleterious effect on the signaling activity of
PROKR2 was, however, confirmed in transfected HEK-293 cells
for most of the mutations (Cole et al., 2008; Monnier et al., 2009).
Then, we considered the possibility that mutations in PROK2
also account for some KS cases, especially since mutant mice defec-
tive in PROK2 showed a marked reduction in the size of their
olfactory bulbs. PROK2 contains four coding exons (Bullock et al.,
2004), of which exon 3, encoding an arginine- and lysine-rich pep-
tide of 21 amino acid residues, may or may not be included in the
mature transcript due to alternative splicing (Wechselberger et al.,
1999) (Figure 1). We sequenced the entire coding sequence of
PROK2 in the patients, and identified four different point muta-
tions (two missense mutations, one frame-shifting mutation, and
one single nucleotide substitution in the translation initiation
sequence), all in the heterozygous state (Dodé et al., 2006). PROK2
mutations in homozygous state were subsequently found in a few
patients, and a KS-like phenotype was concomitantly reported
in PROK2-null mutant mice (Pitteloud et al., 2007; Leroy et al.,
2008). Since then, additional mutations in PROKR2 and PROK2
have been reported in KS patients. A list of the mutations, together
with the corresponding references, is provided in Table 2.
The finding, for given PROKR2 and PROK2 mutations, of
both heterozygous and homozygous (or compound heterozy-
gous) unrelated patients is quite remarkable, and argues in favor
of a digenic or oligogenic mode of inheritance in heterozygous
patients. To date, digenic inheritance of KS has been shown
in few patients who had monoallelic missense mutations both
in PROKR2 or PROK2, and in other KS genes (KAL1, FGFR1)
or genes underlying normosmic congenital hypogonadotropic
hypogonadism (GNRHR, KISS1R) (Dodé et al., 2006; Cole et al.,
2008; Raivio et al., 2009; Martin et al., 2010; Sarfati et al., 2010).
The other patients harboring monoallelic mutations in PROKR2
or PROK2 are expected to carry at least one additional pathogenic
mutation in as yet uncharacterized genes. Indeed, mutations in
any of the currently known KS genes have been identified in only
30% of all KS patients, thus indicating that other disease genes
remain to be discovered. Notably, it has been found that patients
carrying biallelic mutations in PROKR2 or PROK2 consistently
have a severe, complete KS phenotype, whereas the phenotype of
patients carrying monoallelic mutations in these genes is more
variable, and likely depends on the additional genetic hits in these
patients (Martin et al., 2010; Sarfati et al., 2010).
Kallmann syndrome patients who carry biallelic mutations
in PROK2 or PROKR2 do not seem to have any of the non-
olfactory, non-reproductive occasional anomalies that have been
reported in the previously characterized genetic forms of the dis-
ease (i.e., X-linked KAL1 form and autosomal dominant KAL2
form), specifically, bimanual synkinesis, renal agenesis, dental age-
nesis, and cleft lip or palate, and even though sleep disorders
or increased body mass index have been reported in some of
these patients, there is so far no evidence that these clinical fea-
tures can be ascribed to the PROKR2 and PROK2 mutations,
despite potential roles of these genes in sleep-wake regulation
and ingestive behavior (see above). In addition, plasma corti-
sol levels were measured during 24 h in five patients mutated in
PROK2 or PROKR2, including one patient with biallelic PROKR2
mutations, and normal circadian variation was observed in all
cases (Sarfati et al., 2010), which argues against a major contri-
bution of PROK2/PROKR2 signaling to physiological circadian
variation of plasma cortisol levels in humans. Of course, this
result does not exclude the presence of more subtle defects in
the patients.
CONSEQUENCES OF THE PROKR2 AND PROK2 MISSENSE
MUTATIONS ON RECEPTOR SIGNALING ACTIVITY
A total of 24 PROKR2 missense mutations have been identified
(Dodé et al., 2006; Cole et al., 2008; Sinisi et al., 2008; Chan et al.,
2009; Abreu et al., 2010; Sarfati et al., 2010) in KS patients (Table 2;
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Table 2 | PROKR2 and PROK2 mutations in Kallmann syndrome.
Exon Nucleotide
change
Amino acid
change
Localization (domain) Functional consequence Reference
PROKR2
1 58del Frameshift N-terminal region NMD or protein truncation Dodé et al. (2006)
151G>A A51T N-terminal region None? Reynaud et al. (2012), Sbai et al.
(unpublished)
238C>T R80C First intracellular loop None? Abreu et al. (2010), Sbai et al.
(unpublished)
– 253C>T R85C – Mild G protein-coupling defect Cole et al. (2008), Monnier et al. (2009),
Sarfati et al. (2010)
– 253C>G R85G – Strong G protein-coupling defect Sarfati et al. (2010), Raivio et al. (2012)
– 254G>T R85L – Mild protein-coupling defect Sarfati et al. (2010), Sbai et al.
(unpublished)
– 254G>A R85H – Mild G protein-coupling defect Dodé et al. (2006), Monnier et al. (2009)
– 337T>C Y113H First extracellular loop Strong G protein-coupling defect Cole et al. (2008), Sbai et al. (unpublished)
– 343G>A V115M – Strong G protein-coupling defect Cole et al. (2008), Sbai et al. (unpublished)
349C>T R117W – Strong G protein-coupling defect Sbai et al. (unpublished)
– 420C>G Y140X Third transmembrane domain NMD or protein truncation Abreu et al. (2010)
2 491G>A R164Q Second intracellular loop Mild G protein-coupling defect Dodé et al. (2006), Cole et al. (2008),
Monnier et al. (2009)
– 518T>G L173R Fourth transmembrane domain Cell surface-targeting defect Dodé et al. (2006), Abreu et al. (2010),
Cole et al. (2008), Monnier et al. (2009)
– 533G>C W178S – Cell surface-targeting defect Dodé et al. (2006), Cole et al. (2008),
Monnier et al. (2009)
– 563C>T S188L – Strong G protein-coupling defect Cole et al. (2008), Sbai et al. (unpublished)
– 604A>G S202G Second extracellular loop ? Chan et al. (2009)
– 629A>G Q210R – Ligand-binding defect Dodé et al. (2006), Monnier et al. (2009)
701G>A G234D Fifth transmembrane domain Cell surface-targeting defect Sbai et al. (unpublished)
– 743G>A R248Q Third intracellular loop None? Cole et al. (2008)
– 752G>T W251L – Strong G protein-coupling defect? Sarfati et al. (2010), Sbai et al.
(unpublished)
– 802C>T R268C – G protein-coupling defect? Dodé et al. (2006), Abreu et al. (2010),
Monnier et al. (2009), Sarfati et al. (2010)
– T820>A V274D Sixth transmembrane domain Strong G protein-coupling defect Sinisi et al. (2008), Sbai et al.
(unpublished)
– 868C>T P290S – Cell surface-targeting defect Dodé et al. (2006), Monnier et al. (2009)
– 969G>A M323I Seventh transmembrane domain None? Dodé et al. (2006), Monnier et al. (2009)
– 989del Frameshift – NMD or protein truncation Sarfati et al. (2010)
– 991G>A V331M – Mild G protein-coupling defect Dodé et al. (2006), Cole et al. (2008),
Monnier et al. (2009), Sarfati et al. (2010)
– 1069C>T R357W C-terminal region None? Cole et al. (2008), Sbai et al. (unpublished)
(Continued)
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Table 2 | Continued
Exon Nucleotide
change
Amino acid
change
Localization (domain) Functional consequence Reference
PROK2
1 −4C>A Translation initiation site Reduced protein synthesis? Dodé et al. (2006)
– 70G>C A24P Signal peptide ? Cole et al. (2008)
– 94G>C G32R AVITGA motif Strongly impaired activity? Dodé et al. (2006)
2 101 G>A C34Y Cysteine-rich region Strongly impaired activity Cole et al. (2008)
– 137G>A C46Y Cysteine-rich region ? Dodé et al. (unpublished)
– 150C>G I50M – None? Cole et al. (2008)
– 161G>A S54N – ? Sarfati et al. (2010)
– 163del Frameshift – NMD or protein truncation Pitteloud et al. (2007), Leroy et al. (2008)
– 217C>T R73C – Strongly impaired activity Dodé et al. (2006), Leroy et al. (2008),
Cole et al. (2008)
4 297_298insT Frameshift – NMD or protein truncation Dodé et al. (2006), Abreu et al. (2010)
301C>T R101W – ? Dodé et al. (unpublished)
– 302G>A R101Q – ? Dodé et al. (unpublished)
– 310C>T H104Y – ? Sarfati et al. (2010)
Mutations reported in PROKR2 and PROK2 are mainly missense mutations. In most patients, the mutations have been found in heterozygous state.The R85C, R85H,
R164Q, L173R, and P290S PROKR2 mutations, as well as R73C, c.163del, and c.297_298insT PROK2 mutations have, however, been found both in heterozygous and
homozygous (or compound heterozygous) states, which suggests that patients heterozygous for PROKR2 or PROK2 mutations carry additional mutations, presumably
in other, as yet unidentified Kallmann syndrome genes in most cases. Notably, two such patients have the L173R mutation in PROKR2 together with S396L or R423X
mutations in KAL1 (Dodé et al., 2006; Sarfati et al., 2010), another patient has the V115M mutation in PROKR2 together with the A24P mutation in PROK2 (Cole et al.,
2008), and still another patient has the R85L mutation in PROKR2 together with a A604T mutation in FGFR1 (Sarfati et al., 2010). In addition, the patient who has the
S202G mutation in PROKR2 also has I239T and R31C monoallelic mutations in FGFR1 and GNRH1, respectively (Chan et al., 2009). Finally, two patients who carry
R268C and V331M mutations in PROKR2 also carry A189T and R240Q monoallelic mutations in KISS1R and GNRHR, respectively (Sarfati et al., 2010). Abbreviation:
NMD, nonsense-mediated mRNA decay.
?, not known.
FIGURE 1 | PROK2 gene structure and amino acid sequence.The green box and green amino acid sequence denote the alternative exon and encoded
peptide, respectively. The AVITGA motif is shown in red, and the 10 cysteinyl residues (forming five disulfide bonds) are in blue. Vertical arrows indicate the
positions of the mutations identified in the patients.
Figure 2). Most of the mutant receptors have been character-
ized regarding their ability to induce intracellular release of cal-
cium upon PROK2-stimulation, their cell surface expression, and
their PROK2-binding, in mammalian cell lines (Cole et al., 2008;
Monnier et al., 2009; Abreu et al., 2012; Raivio et al., 2012; Sbai
et al., in preparation). Although PROKR2 can activate different
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FIGURE 2 | Positions of missense mutations in PROK2 and PROKR2 in
the structural models of the ligand and the receptor.The mutations are
classified in different categories according to their effects on PROKR2
signaling activity: similar to wild-type (green), absence of the receptor at
the cell surface (brown), absence of ligand-binding (blue), and strong or mild
effect on signaling (red and orange, respectively). The mutations for which
functional data are not available are denoted in black. The colored balls
indicate the atom of alpha carbon of the polypeptidic chain of the mutated
residue. Note that residue R357 is located in the proximal part of the
C-terminal region of the receptor.
G protein pathways (Lin et al., 2002; Soga et al., 2002; Chen
et al., 2005), its coupling to Gq, leading to intracellular release
of calcium, represents the best characterized transduction mech-
anism. Only five mutants (A51T, R80C, R248Q, M321I, R357W)
have properties similar to the wild-type PROKR2, thus calling
into question the pathogenic effect of these missense variants.
Notably, the R268C mutation has also been found in heterozy-
gous state in a relatively large proportion (174 out of 2203, i.e.,
7.9%) of individuals from the African American general pop-
ulation, and in homozygous state in six individuals from the
same population (0.3%; see Exome Variant Server website URL:
http://evs.gs.washington.edu/EVS/). Moreover, a clear deleterious
effect of the R268C mutation on PROKR2 signaling through Gq
protein activation could not be found in transfected HEK-293 cells,
thus calling into question the pathogenic effect of this missense
variant too. Most of the PROKR2 mutations, however, impair cell
surface expression, ligand-binding, or G protein-binding of the
receptor (Figure 2). Three mutations affecting conserved residues
located in the middle of the transmembrane helices, W178S,
G234D, and P290S, impede targeting of the receptor to the cell
surface. The Q210R mutant receptor is present at the cell sur-
face, but is not able to bind to the ligand. The other mutants
impair, either mildly or strongly, intracellular release of calcium
in the Gq signaling pathway, and for some of them this effect
might be due to the low expression of the mutant at the cell
surface. Interestingly, the mutations that mostly impair the sig-
naling are located nearby the extracellular side or the intracellular
side of the receptor, and for these mutants, the loss-of-function
is associated to a loss of cell surface expression. The mutations
that result in a mildly impaired signaling activity are located
in the intracellular loops, in agreement with the important role
played by these loops in G protein-coupling. In addition, when
wild-type and mutant receptors were coexpressed in HEK-293
cells, none of the mutant receptors that were retained within
the cells did affect cell surface-targeting of the wild-type recep-
tor, and none of the mutant receptors properly addressed at the
plasma membrane did affect wild-type receptor signaling activity.
This argues against a dominant negative effect of the mutations
in vivo.
A total of 10 missense mutations have been identified in
PROK2 (Table 2, Figure 2) (Dodé et al., 2006; Cole et al., 2008;
Leroy et al., 2008; Sarfati et al., 2010). A mutation located at the
translation initiation site (−4C>A) likely reduced the protein
synthesis. Mutations of conserved residues in prokineticins are
expected to strongly impair PROK2 activity such as those in the
N-terminal conserved region AVITGA important for prokineticin
activity (G32R), and those of the conserved cysteines (C34Y and
C46Y). In addition, mutations that introduce an additional cys-
teine (R73C) in the cysteine-rich region of PROK2 may affect
folding of the hormone then leading to a loss-of-function. This is
consistent with the functional analysis of Cole et al. (2008) who
have examined the signaling properties of three PROK2 mutants:
the C34Y and R73C mutations totally abolished and strongly
impaired the intracellular calcium release activity of PROKR2,
respectively, whereas the I50M mutation had an activity similar
to that of the wild-type PROK2. The functional consequence of
the other mutations (A24P, S54N, R101Q, R101W, and H104Y)
are more difficult to predict in the absence of model of the
complex between PROK2 and PROKR2. Further studies will be
necessary to better analyze whether the mutations in PROK2
affect the process of binding and/or activation of PROKR2 by
the hormone.
CONCLUSION
The characterization of new genes involved in KS is a difficult
goal. Because of the hypogonadotropic hypogonadism, sizes of
the KS families are small and the mode of inheritance is very
often difficult to establish. Animal models in which a gene has
been inactivated and involving a KS phenotype are an alter-
native approach for the identification of new KS genes. The
inactivation of PROK2 or PROKR2 lead to defective olfactory
morphogenesis and hypogonadism in mice and humans. Curi-
ously, PROK2 and PROKR2 mutations in homozygous state
were found in a few patients and the main part of the KS
patients carried only heterozygous mutations. In all of the func-
tional studies done so far, only Gq signaling pathways have been
investigated to characterize the PROK2 and PROKR2 mutants
and further studies will be necessary to analyze other signal-
ing pathways. Interestingly, few patients who had monoallelic
Frontiers in Endocrinology | Neuroendocrine Science April 2013 | Volume 4 | Article 19 | 6
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missense mutations both in PROK2 or PROKR2, and in other
KS or normosmic congenital hypogonadotropic hypogonadism
genes, raising the idea of oligogenism. So far, this hypothe-
sis has been validated only in a few patients suggesting that
the second mutation in the other heterozygous patients resides
in unexplored regions of the genes or as yet undiscovered KS
genes.
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